Abstract |
We retrospectively studied a cohort of 144 adults with Philadelphia chromosome/BCR-ABL1 positive B acute lymphoblastic leukemia (Ph + B-ALL) to assess the clinical implications of cytogenetic heterogeneity in this disease. The study group included 85 men and 59 women that were sorted into 6 subgroups based on karyotypic findings in the stemline as follows: 32 patients with t(9;22) as a sole aberration, 23 with t(9;22) plus 1 additional chromosomal abnormality (ACA), 26 with t(9;22) as part of a complex karyotype, 18 showing a variant-/complex- t(9;22), 30 with t(9;22) as the stemline with ACAs in the sideline(s), and 15 patients who had the t(9;22) and hyperdiploidy. In 89 patients 1 clone was identified; 41 had 2 clones and 14 had ≥ 3 clone(s). The median overall survival (OS) was 25.6 months and the median relapse-free survival (RFS) was 20.6 months. Patients with variant-/complex- t(9;22) had poorer OS and RFS when compared with all other subgroups combined (P = 0.0018 and P = 0.0049, respectively). In addition, patients with ≥ 2 clones had worse OS and RFS than patients with 1 clone (P = 0.0179 and P = 0.0429, respectively). Multivariate analysis confirmed that variant-/complex-t(9;22) and clone number are independent risk factors. We suggest that conventional chromosomal analysis is of clinical importance for risk stratification of B-ALL patients.
|
Authors | Poonam Jain, Jun Gu, Rashmi Kanagal-Shamanna, Zhenya Tang, Keyur P Patel, Hui Yao, Lianghua Fang, Hai-Yan Bao, Ching-Hua Liu, Pei Lin, L Jeffrey Medeiros, Xinyan Lu |
Journal | Leukemia research
(Leuk Res)
Vol. 84
Pg. 106176
(09 2019)
ISSN: 1873-5835 [Electronic] England |
PMID | 31279181
(Publication Type: Journal Article)
|
Copyright | Copyright © 2019 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antineoplastic Agents
- Protein Kinase Inhibitors
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(administration & dosage, adverse effects, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Chromosome Aberrations
- Cytogenetic Analysis
- Female
- Genetic Association Studies
- Genetic Heterogeneity
- Genetic Predisposition to Disease
- Humans
- Immunophenotyping
- In Situ Hybridization, Fluorescence
- Kaplan-Meier Estimate
- Karyotype
- Male
- Middle Aged
- Philadelphia Chromosome
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
(diagnosis, drug therapy, genetics, mortality)
- Protein Kinase Inhibitors
(administration & dosage, adverse effects, therapeutic use)
- Treatment Outcome
- Young Adult
|